$INV

Innventure, Inc. (INV): Results of Operations and Financial Condition

Innventure, Inc. (INV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Innventure Reports Second Quarter 2026 Results Accelsius focused on execution against foundational milestones to strengthen path to scaled two-phase adoption ORLANDO, Fla., August 13, 2026 (GLOBAL NEWSWIRE) – Innventure, Inc. (NASDAQ: INV) (“Innventure”), an industri

Original reporting
Published Aug 13, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$INV
Bearish
medium confidence
Mentioned
$INV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$INVBearishMed
01

Why it matters

Management suspended previously communicated 2026 revenue and cash flow targets for Accelsius, citing evolving AI infrastructure market dynamics and constraints affecting smaller early adopters’ power availability, GPU access, and deployment timing.

02

Market read

Guidance suspension is the primary market-relevant signal, likely resetting expectations for 2026 cash generation tied to scaled adoption milestones.

03

What to watch

The excerpt does not include the actual 2Q financial figures or updated milestone timelines, so traders may overreact until the full EX-99.1 tables and call Q&A clarify cash runway and milestone probability.

Relevance 7/10Novelty 6/10Timing: after-hours today, ahead of the 5:00 pm ET conference call
AlphAI · Earnings readINV · Second Quarter 2026 · ended June 30, 2026

Innventure Reports Second Quarter 2026 Results; suspends previously communicated Accelsius 2026 revenue and cash flow expectations to focus on milestones for scaled two-phase adoption.

Mixed quarter

Quarterly revenue increased to $ 953 from $ 476 and the quarterly net loss narrowed to $ (34,914) from $ (141,275), with no goodwill impairment in 2026. However, revenue remained below cost of sales, Adjusted EBITDA was negative, operating cash use was $ (59,466), and management suspended its previously communicated Accelsius 2026 revenue and cash flow expectations.

Revenue
$ 953
EPS · GAAP
$ (0.32)

Key metrics

as reported
MetricValueq/qy/y
RevenueGAAP$ 953
Cost of salesGAAP5,073
General and administrative expenseGAAP14,499
Sales and marketing expenseGAAP3,089
Research and development expenseGAAP9,780
Goodwill impairmentGAAP
Total Operating ExpensesGAAP32,441
Loss from OperationsGAAP(31,488)
Interest expense, netGAAP(531)
Net gain (loss) from investmentsGAAP39
Change in fair value of financial liabilitiesGAAP(2,188)
Equity method investment (loss) incomeGAAP(1,491)
Loss on extinguishment of debtGAAP
Miscellaneous other expenseGAAP(773)
Loss before Income TaxesGAAP(36,432)
Income tax benefitGAAP(1,518)
Net LossGAAP(34,914)
Net loss attributable to Non-redeemable non-controlling interestGAAP(8,411)
Net Loss Attributable to Innventure, Inc. Stockholders / Innventure LLC UnitholdersGAAP(26,503)
Basic and diluted loss per shareGAAP$ (0.32)
Basic and diluted weighted average common sharesGAAP83,117,031
EBITDAnon-GAAP(30,241)
Adjusted EBITDAnon-GAAP(22,576)
Six Months Ended June 30, 2026 RevenueGAAP$ 2,396
Six Months Ended June 30, 2026 Loss from OperationsGAAP(58,785)
Six Months Ended June 30, 2026 Net LossGAAP(62,697)
Six Months Ended June 30, 2026 Net Loss Attributable to Innventure, Inc. Stockholders / Innventure LLC UnitholdersGAAP(47,308)
Six Months Ended June 30, 2026 Basic and diluted loss per shareGAAP$ (0.59)
Six Months Ended June 30, 2026 Adjusted EBITDAnon-GAAP(40,992)

Capital returns

  • Distributions to Stockholders: — for the Three Months Ended June 30, 2026; (76) for the Three Months Ended June 30, 2025.
  • Proceeds from issuance of equity, net of issuance costs: 50,229 for the Three Months Ended June 30, 2026; 3,675 for the Three Months Ended June 30, 2025.

What drove it

  • Management cited anticipated significant long-term demand for two-phase liquid cooling as AI infrastructure requirements accelerate.
  • Accelsius is focused on chip-maker relationships and reference designs, OEM and ODM co-development initiatives, hyperscaler relationships, and delivery of additional thermal benchmark data.
  • Management cited momentum at AeroFlexx and Refinity.
  • The quarterly reduction in GAAP losses versus the prior-year period reflected, in part, the absence of goodwill impairment in the 2026 period.

Concerns

  • Innventure suspended its previously communicated expectations regarding Accelsius' 2026 revenue and cash flow targets.
  • Management said constraints facing smaller early adopters around power availability, GPU access, and deployment timing have affected near-term expectations.
  • Quarterly revenue of $ 953 was below cost of sales of 5,073.
  • Adjusted EBITDA was (22,576), compared with (16,178) in the prior-year quarter.
  • Net Cash Used in Operating Activities was (59,466) for the Three Months Ended June 30, 2026, while Cash Flows Provided by Financing Activities were 41,634.

What to watch

  • Progress in chip-maker relationships, reference designs, OEM and ODM co-development initiatives, hyperscaler relationships, and additional thermal benchmark data.
  • Whether Accelsius advances the foundational milestones management identified as necessary for scaled market adoption of two-phase liquid cooling.
  • Revenue generation and operating cash flow following the suspension of Accelsius' previously communicated 2026 targets.
  • Cash and financing activity following cash and cash equivalents of $ 41,543 as of June 30, 2026 and proceeds from issuance of equity, net of issuance costs, of 50,229 for the Three Months Ended June 30, 2026.

Balance sheet and cash flow

  • Cash and cash equivalents: $ 41,543 as of June 30, 2026; $ 60,449 as of December 31, 2025.
  • Restricted cash: 5,000 as of June 30, 2026; 5,000 as of December 31, 2025.
  • Total Current Assets: 71,439 as of June 30, 2026; 83,154 as of December 31, 2025.
  • Total Assets: $ 574,697 as of June 30, 2026; $ 599,187 as of December 31, 2025.
  • Total Current Liabilities: 59,767 as of June 30, 2026; 76,276 as of December 31, 2025.
  • Notes payable - current: 7,700 as of June 30, 2026; 12,846 as of December 31, 2025.
  • Term convertible note, current: 8,026 as of June 30, 2026; 7,890 as of December 31, 2025.
  • Convertible promissory note, current: 4,407 as of June 30, 2026; 4,331 as of December 31, 2025.
  • Notes payable, net of current portion: 5,909 as of June 30, 2026; 8,327 as of December 31, 2025.
  • Total Liabilities: 91,882 as of June 30, 2026; 115,511 as of December 31, 2025.
  • Total Stockholders' Equity: 482,815 as of June 30, 2026; 483,676 as of December 31, 2025.
  • Net Cash Used in Operating Activities: (59,466) for the Three Months Ended June 30, 2026; (36,754) for the Three Months Ended June 30, 2025.
  • Acquisition of property, plant and equipment: (1,074) for the Three Months Ended June 30, 2026; (932) for the Three Months Ended June 30, 2025.
  • Net Cash (Used in) Provided by Investing Activities: (1,074) for the Three Months Ended June 30, 2026; (3,640) for the Three Months Ended June 30, 2025.
  • Cash Flows Provided by Financing Activities: 41,634 for the Three Months Ended June 30, 2026; 41,240 for the Three Months Ended June 30, 2025.
  • Net Decrease in Cash, Cash Equivalents and Restricted Cash: (18,906) for the Three Months Ended June 30, 2026; 846 for the Three Months Ended June 30, 2025.
  • Cash, Cash Equivalents and Restricted Cash End of period: $ 46,543 for the Three Months Ended June 30, 2026; $ 11,965 for the Three Months Ended June 30, 2025.

Analysis

Innventure reported quarterly revenue of $ 953, versus $ 476 in the prior-year quarter. Cost of sales was 5,073, while research and development expense was 9,780 and sales and marketing expense was 3,089. The release frames the operating focus around Accelsius and foundational adoption milestones for two-phase liquid cooling rather than near-term revenue generation.

The GAAP net loss narrowed to (34,914) from (141,275), and loss from operations narrowed to (31,488) from (142,574). The prior-year quarter included 113,344 of goodwill impairment, while the 2026 quarter reported no goodwill impairment. Excluding the identified non-GAAP adjustments, Adjusted EBITDA was (22,576), compared with (16,178), so the adjusted operating loss was larger than in the prior-year quarter despite the improvement in the GAAP loss.

Innventure reported $ 41,543 of cash and cash equivalents as of June 30, 2026, down from $ 60,449 at December 31, 2025. The cash flow statement reports Net Cash Used in Operating Activities of (59,466) for the Three Months Ended June 30, 2026, acquisition of property, plant and equipment of (1,074), and Cash Flows Provided by Financing Activities of 41,634. Proceeds from issuance of equity, net of issuance costs, were 50,229 in the stated period.

The release does not provide numerical forward guidance. Instead, management suspended its previously communicated Accelsius 2026 revenue and cash flow targets, citing power availability, GPU access, and deployment-timing constraints affecting smaller early adopters. The central operating question is execution on chip-maker, OEM, ODM, hyperscaler, and thermal-benchmark milestones that management says govern scaled adoption.

For the six months ended June 30, 2026, revenue was $ 2,396 versus $ 700, net loss was (62,697) versus (394,949), and Adjusted EBITDA was (40,992) versus (38,002). The period shows increased reported revenue and a sharply reduced GAAP loss after the prior-year goodwill impairment, but continuing negative adjusted profitability, operating cash use, and the removal of numerical Accelsius targets place emphasis on commercial and adoption milestones.

Management, verbatim

We firmly believe the industry is moving toward a future where two-phase liquid cooling becomes an essential part of AI infrastructure.

Bill Haskell, Chief Executive Officer

While our conviction in Accelsius’ long-term opportunity has only strengthened, evolving dynamics in the AI infrastructure market, including constraints facing smaller early adopters around power availability, GPU access, and deployment timing, have impacted our near-term expectations and render 2026 revenue generation an imprecise reflection of the meaningful progress Accelsius is making.

Bill Haskell, Chief Executive Officer

As a result, we are suspending our previously communicated expectations regarding Accelsius’ 2026 revenue and cash flow targets and shifting our focus to execution against important milestones that govern scaled market adoption, which include forging strong relationships with industry leaders.

Bill Haskell, Chief Executive Officer

Not in the filing

stated, not guessed
  • Segment revenue, segment year-over-year changes, segment quarter-over-quarter changes, and segment profitability were not reported.
  • Gross profit and gross margin were not reported.
  • Prior-quarter comparisons for quarterly operating metrics were not reported.
  • Non-GAAP EPS was not reported.
  • Free cash flow was not reported.
  • A numerical 2026 or other forward revenue, gross margin, operating expense, tax-rate, or cash-flow outlook was not reported.
  • Prior outlook was not provided, so a comparison of reported results with prior guidance cannot be made.
  • The filing does not provide a specific driver for each expense-line change or for the reported revenue change.
  • The cash flow statement labels its columns as Three Months Ended June 30, 2026 and Three Months Ended June 30, 2025, while its Net loss line reports $ (62,697) and $ (394,949), respectively; no alternative period label is supplied for those cash-flow figures.

AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

This is an SEC Form 8-K (Item 2.02) with an attached earnings release for Innventure’s quarter ended June 30, 2026, focused on its Accelsius two-phase liquid cooling thesis.

Company-level read

Ticker impact

$INVBearishMedium confidence
Context

Innventure reports 2Q 2026 results and suspends previously communicated 2026 revenue and cash flow targets for its Accelsius business.

Expected impact

Near-term downside bias versus prior expectations, with volatility around the 5:00 pm ET earnings call and any follow-on milestone updates.

Evidence & confidence

The filing is a fresh 8-K with a specific decision to suspend 2026 revenue and cash flow targets, which typically resets investor expectations even without new numeric guidance in the excerpt.

Market effects

Highlights uncertainty in near-term adoption timing for two-phase liquid cooling tied to AI infrastructure constraints, which can affect sentiment toward thermal management/AI infrastructure supply chains.

Limited direct regional read-through; primarily impacts US-listed small/mid-cap industrial growth narrative.

Two-phase liquid cooling demand framing is global, but the disclosed impact is company-specific and guidance-related.

Counterpoint

Suspending targets may reflect conservatism rather than deterioration, since management says long-term conviction strengthened and points to momentum at AeroFlexx and Refinity.

Key entities

  • Innventure, Inc.

    NASDAQ-listed industrial growth conglomerate reporting 2Q 2026 results and suspending 2026 Accelsius revenue and cash flow targets.

  • Accelsius

    Innventure’s two-phase liquid cooling initiative whose 2026 targets were suspended due to changing adoption dynamics.

Every INV earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$INVLow

INV Court Alert: Innventure Securities Fraud Class Action Deadline is Approaching on October 27 for Investors that Suffered Losses

Innventure Inc. (INV) faces a securities fraud class action lawsuit over alleged misrepresentations about Accelsius' DarkNX data center deal. The stock dropped 55% in August 2026 after Innventure suspended revenue targets, following a May 2026 report questioning the deal's validity. Investors have until October 27, 2026, to join the lawsuit.

$INVMed

Innventure (INV) Q2 2026 Earnings Call Transcript

Innventure (INV) reported Q2 2026 revenue of $1M, up from $0.5M YoY, driven by Accelsius. Net loss widened to $34.9M vs. $27.8M QoQ. CEO Bill Haskell to retire; Bill Grieco to succeed. Accelsius faces adoption delays due to infrastructure constraints, shifting focus to hyperscalers. Cash position at $46.5M, down from $60.4M. Management withdrew 2028 cash flow target.

$INVMed

Placing and Offer for Subscription

The Board of The Investment Company plc (LSE: INV) published a circular to shareholders on 4 June 2026 outlining proposals for the company’s future. Plans include appointing Dowgate Wealth Limited as portfolio manager, adopting a new scarcity/resilience-focused investment policy, raising funds via a placing and offer for subscription, and providing a 100% exit option for qualifying shareholders not wishing to stay. Proposals require shareholder approval.

$INVMedAI 9/10

Innventure (INV) Q4 2025 Earnings Transcript

Innventure (INV) reported 2025 revenue of $2.1m vs. $1.2m in 2024, driven by Accelsius and AeroFlexx. Accelsius delivered $1.6m revenue (vs. $0.3m) and secured $50m+ in new Q1 bookings; Accelsius Series B closed at a ~$665m post-money valuation. Management expects Accelsius to be cash-flow positive by year-end. Cash rose to $65.4m; adjusted EBITDA loss was $78.8m.

$NVOHighAI 8/10

Novo Nordisk shares fall by up to 7% in Denmark — CNBC

Novo Nordisk shares dropped 7% in early trading on September 21, 2026, after the company announced new growth targets for its obesity treatment drugs. The firm aims to launch over five potential multi-blockbuster drugs by 2030 and expects sales of over 150 billion Danish kroner ($23 billion) by 2035. Novo Nordisk also anticipates matching industry revenue growth rates from 2026 to 2030.